Fewer than a tenth of people that would benefit from obesity jabs like Wegovy have access to them, warns the global health agency as it releases its first advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidance acknowledges that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major barriers to broad access to the jabs that can aid individuals in losing substantial weight, says the organization.
Skinny Jab Supply Crisis
Despite the present most favorable outlook, the manufacturing of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, per the WHO.
The advice urges nations and manufacturers to widen access, by approaches such as patent sharing.
A patent on semaglutide – the core ingredient of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Injections Function
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and increase the sense of being full so people eat less.
Individuals usually begin shedding pounds in the initial weeks of commencing the regular doses.
Research indicates people may put most of the weight back on within a year of halting the medication, as their usual appetite come back.
Being carrying excess weight increases your likelihood for developing diseases, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
